|1.||Houen, Gunnar: 2 articles (02/2013 - 01/2013)|
|2.||Welner, Simon: 2 articles (02/2013 - 01/2013)|
|3.||Davaris, P: 2 articles (01/2003 - 09/2001)|
|4.||Korkolopoulou, P: 2 articles (01/2003 - 09/2001)|
|5.||Patsouris, E: 2 articles (01/2003 - 09/2001)|
|6.||Konstantinidou, A E: 2 articles (01/2003 - 09/2001)|
|7.||Haug, C S: 1 article (01/2016)|
|8.||Sundstrøm, S: 1 article (01/2016)|
|9.||Habberstad, A H: 1 article (01/2016)|
|10.||Torp, S H: 1 article (01/2016)|
|1.||Melanoma (Melanoma, Malignant)
|2.||Astrocytoma (Pilocytic Astrocytoma)
01/01/2016 - "The objective of this study was to evaluate the diagnostic and prognostic value of the proliferation markers mitosin and phosphohistone H3 (pHH3) in infiltrative astrocytomas WHO grades II and III and compare the findings with mitotic count and Ki-67/MiB-1 immunostaining. "
01/01/2016 - "In conclusion, mitosin and pHH3 immunostaining have prognostic and diagnostic value in the clinical assessment of patients with infiltrative astrocytomas. "
01/01/2016 - "The number of mitoses, pHH3 mitotic figures (MFs), the Ki-67/MiB-1 PI and the mitosin PI were greater in WHOgrade III anaplastic astrocytomas compared to WHO grade II diffuse astrocytomas, while pHH3 PI only showed a trend. "
01/01/2016 - "Fifty-nine and thirty-three infiltrative astrocytomas WHO grades II and III, respectively, were immunostained with the proliferation markers mitosin and pHH3 using standard immunohistochemical procedures. "
01/01/2016 - "Mitosin and pHH3 predict poorer survival in astrocytomas WHO grades II and III."
|3.||Breast Neoplasms (Breast Cancer)
12/15/1997 - "These preliminary results suggest that mitosin as assessed by IHC may be superior to SPF as a prognostic factor in node-negative breast cancer, but additional studies are necessary to validate these promising findings."
12/15/1997 - "Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer."
04/01/2007 - "CENP-F protein expression was evaluated by immunohistochemistry in 91 primary breast cancer samples from cohort I and 289 samples from cohort II. CENP-F correlated with markers of aggressive tumor behavior including ER negativity and high tumor grade. "
01/01/2008 - "Expression of centromere protein F (CENP-F) associated with higher FDG uptake on PET/CT, detected by cDNA microarray, predicts high-risk patients with primary breast cancer."
06/01/2005 - "Previous studies have demonstrated that one of the targets of such ANAs could be the CENP-F protein, especially in some carcinomas. "
06/15/2002 - "The current results indicate that tumor nuclear grade and tumor proliferative activity (mitotic activity and mitosin immunostaining) of pretreatment tumors in patients with breast carcinoma may serve as important indicators for the pathologic responsiveness of tumors to neoadjuvant, anthracycline-based chemotherapy."
09/01/2015 - "Silencing of centromere protein F significantly inhibited cancer cell migration and invasion. "
01/01/2008 - "We identified centromere protein F (CENP-F) and CDC6 were upregulated in tumors with high SUVs. "
01/01/2003 - "In multivariate analysis, the labeling indices of mitosin (p = 0.035) and Ki-67 (p = 0.032), along with tumor size, were shown to provide independent prognostic information, beyond that obtained by standard clinical and pathological parameters. "
01/01/2003 - "Univariate analysis disclosed mitosin LI (p = 0.033) along with the mitotic index (p = 0.024) and tumor size (p = 0.028) as significant predictors of shortened recurrence-free survival. "
06/15/2002 - "Nuclear grade, mitotic activity, and biomarker profile (Her2-neu and mitosin expression patterns) in pretreatment tumors were correlated with the postchemotherapy pathologic response. "
|1.||Type I DNA Topoisomerases (Topoisomerase I)
|3.||centromere protein F
|4.||Complementary DNA (cDNA)
|5.||Proliferating Cell Nuclear Antigen (PCNA)
|7.||Messenger RNA (mRNA)
|8.||Progesterone Receptors (Progesterone Receptor)
|1.||Bone Marrow Transplantation (Transplantation, Bone Marrow)
|2.||Drug Therapy (Chemotherapy)